Silencing neurodegenerative disease: bringing RNA interference to the clinic

References

• Fire A, Xu S, Montgomery MK et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391(6669), 806–811 (1998).
   PubMed Web of Science ®Google Scholar
• Mello CC, Conte D Jr. Revealing the world of RNA interference. Nature 431(7006), 338–342 (2004).
   PubMed Web of Science ®Google Scholar
• Hannon GJ, Rossi JJ. Unlocking the potential of the human genome with RNA interference. Nature 431(7006), 371–378 (2004).
   PubMed Web of Science ®Google Scholar
• Shankar P, Manjunath N, Lieberman J. The prospect of silencing disease using RNA interference. JAMA 293(11), 1367–1373 (2005).
   PubMed Web of Science ®Google Scholar
• Stevenson M. Therapeutic potential of RNA interference. N. Engl. J. Med. 351(17), 1772–1777 (2004).
   PubMed Web of Science ®Google Scholar
• Dykxhoorn DM, Lieberman J. The silent revolution: RNA interference as basic biology, research tool, and therapeutic. Annu. Rev. Med. 56, 401–423 (2005).
   PubMed Web of Science ®Google Scholar
• Izquierdo M. Short interfering RNAs as a tool for cancer gene therapy. Cancer Gene Ther. 12(3), 217–227 (2005).
   PubMed Web of Science ®Google Scholar
• Berkhout B. RNA interference as an antiviral approach: targeting HIV-1. Curr. Opin. Mol. Ther. 6(2), 141–145 (2004).
   PubMed Web of Science ®Google Scholar
• Davidson BL, Paulson HL. Molecular medicine for the brain: silencing of disease genes with RNA interference. Lancet Neurol. 3(3), 145–149 (2004).
   PubMed Web of Science ®Google Scholar
• Zamore PD, Haley B. Ribo-gnome: the big world of small RNAs. Science 309(5740), 1519–1524 (2005).
   PubMed Web of Science ®Google Scholar
• Kim VN. MicroRNA biogenesis: co-ordinated cropping and dicing. Nature. Rev. Mol. Cell Biol. 6(5), 376–385 (2005).
   PubMed Web of Science ®Google Scholar
• Tomari Y, Zamore PD. MicroRNA biogenesis: drosha can’t cut it without a partner. Curr. Biol. 15(2), R61–R64 (2005).
   PubMed Web of Science ®Google Scholar
• Cullen BR. Transcription and processing of human microRNA precursors. Mol. Cell 16(6), 861–865 (2004).
   PubMed Web of Science ®Google Scholar
• Murchison EP, Hannon GJ. miRNAs on the move: miRNA biogenesis and the RNAi machinery. Curr. Opin. Cell Biol. 16(3), 223–229 (2004).
   PubMed Web of Science ®Google Scholar
• Tomari Y, Zamore PD. Perspective: machines for RNAi. Genes Dev. 19(5), 517–529 (2005).
   PubMed Web of Science ®Google Scholar
• Meister G,Tuschl T. Mechanisms of gene silencing by double-stranded. RNA Nature 431(7006) 343–349 (2004).
   Google Scholar
• Zeng Y, Cullen BR. Efficient processing of primary microRNA hairpins by Drosha requires flanking nonstructured RNA sequences. J. Biol. Chem. 280(30), 27595–27603 (2005).
   PubMed Web of Science ®Google Scholar
• Lee Y, Ahn C, Han J et al. The nuclear RNase III Drosha initiates microRNA processing. Nature 425(6956), 415–419 (2003).
   PubMed Web of Science ®Google Scholar
• Lund E, Guttinger S, Calado A, Dahlberg JE, Kutay U. Nuclear export of microRNA precursors. Science 303(5654), 95–98 (2004).
   PubMed Web of Science ®Google Scholar
• Carmell MA, Hannon GJ. RNase III enzymes and the initiation of gene silencing. Nature Struct. Mol. Biol. 11(3), 214–218 (2004).
   PubMed Web of Science ®Google Scholar
• Bernstein E, Caudy AA, Hammond SM, Hannon GJ. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 409(6818), 363–366 (2001).
   PubMed Web of Science ®Google Scholar
• Tomari Y, Matranga C, Haley B, Martinez N, Zamore PD. A protein sensor for siRNA asymmetry. Science 306(5700), 1377–1380 (2004).
   PubMed Web of Science ®Google Scholar
• Matranga C, Tomari Y, Shin C, Bartel DP, Zamore PD. Passenger-strand cleavage facilitates assembly of siRNA into Ago2-containing RNAi enzyme complexes. Cell 123(4), 607–620 (2005).
   PubMed Web of Science ®Google Scholar
• Rand TA, Petersen S, Du F, Wang X. Argonaute2 cleaves the antiguide strand of siRNA during RISC activation. Cell 123(4), 621–629 (2005).
   PubMed Web of Science ®Google Scholar
• Gregory RI, Chendrimada TP, Cooch N, Shiekhattar R. Human RISC couples microRNA biogenesis and posttranscriptional gene silencing. Cell 123(4), 631–640 (2005).
   PubMed Web of Science ®Google Scholar
• Khvorova A, Reynolds A, Jayasena SD. Functional siRNAs and miRNAs exhibit strand bias. Cell 115(2), 209–216 (2003).
   PubMed Web of Science ®Google Scholar
• Schwarz DS, Hutvagner G, Du T et al. Asymmetry in the assembly of the RNAi enzyme complex. Cell 115(2), 199–208 (2003).
   PubMed Web of Science ®Google Scholar
• Ralph GS, Mazarakis ND, Azzouz M. Therapeutic gene silencing in neurological disorders, using interfering RNA J. Mol. Med. 83(6), 413–419 (2005).
   Google Scholar
• Forte A, Cipollaro M, Cascino A, Galderisi U. Small interfering RNAs and antisense oligonucleotides for treatment of neurological diseases. Curr. Drug Targets 6(1), 21–29 (2005).
   PubMed Web of Science ®Google Scholar
• Xia H, Mao Q, Eliason SL et al. RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nature. Med. 10(8), 816–820 (2004).
   PubMed Web of Science ®Google Scholar
• Ralph GS, Radcliffe PA, Day DM et al. Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nature Med. 11(4), 429–433 (2005).
   PubMed Web of Science ®Google Scholar
• Raoul C, Abbas-Terki T, Bensadoun JC et al. Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nature Med. 11(4), 423–428 (2005).
   PubMed Web of Science ®Google Scholar
• Harper SQ, Staber PD, He X et al. RNA interference improves motor and neuropathological abnormalities in a Huntington’s disease mouse model. Proc. Natl Acad. Sci. USA 102(16), 5820–5825 (2005).
   PubMed Web of Science ®Google Scholar
• Rodriguez-Lebron E, Denovan-Wright EM, Nash K, Lewin AS, Mandel RJ. Intrastriatal rAAV-mediated delivery of antihuntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington’s disease transgenic mice. Mol. Ther. 12(4), 618–633 (2005).
   Google Scholar
• Ding H, Schwarz DS, Keene A et al. Selective silencing by RNAi of a dominant allele that causes amyotrophic lateral sclerosis. Aging Cell2(4), 209–217 (2003).
   PubMed Web of Science ®Google Scholar
• Miller VM, Gouvion CM, Davidson BL, Paulson HL. Targeting Alzheimer’s disease genes with RNA interference: an efficient strategy for silencing mutant alleles. Nucleic. Acids Res. 32(2), 661–668 (2004).
   PubMed Web of Science ®Google Scholar
• Miller VM, Xia H, Marrs GL et al. Allele-specific silencing of dominant disease genes. Proc. Natl Acad. Sci. USA 100(12), 7195–7200 (2003).
   PubMed Web of Science ®Google Scholar
• Gonzalez-Alegre P, Miller VM, Davidson BL, Paulson HL. Toward therapy for DYT1 dystonia: allele-specific silencing of mutant TorsinA. Ann. Neurol. 53(6), 781–787 (2003).
   PubMed Web of Science ®Google Scholar
• Gonzalez-Alegre P, Bode N, Davidson BL, Paulson HL. Silencing primary dystonia: lentiviral-mediated RNA interference therapy for DYT1 dystonia. J. Neurosci. 25(45),10502–10509 (2005).
   Google Scholar
• Abdelgany A, Wood M, Beeson D. Allele-specific silencing of a pathogenic mutant acetylcholine receptor subunit by RNA interference. Hum. Mol. Genet. 12(20), 2637–2644 (2003).
   PubMed Web of Science ®Google Scholar
• Kao SC, Krichevsky AM, Kosik KS, Tsai LH. BACE1 suppression by RNA interference in primary cortical neurons. J. Biol. Chem. 279(3), 1942–1949 (2004).
   PubMed Web of Science ®Google Scholar
• Singer O, Marr RA, Rockenstein E et al. Targeting BACE1 with siRNAs ameliorates Alzheimer’s disease neuropathology in a transgenic model. Nature Neurosci. 8(10),1343–1349 (2005).
   Google Scholar
• Eriksen JL, Przedborski S, Petrucelli L. Gene dosage and pathogenesis of Parkinson’s disease. Trends Mol. Med. 11(3), 91–96 (2005).
   PubMed Web of Science ®Google Scholar
• Elbashir SM, Harborth J, Lendeckel W et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411(6836), 494–498 (2001).
   PubMed Web of Science ®Google Scholar
• Elbashir SM, Lendeckel W, Tuschl T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev. 15(2), 188–200 (2001).
   PubMed Web of Science ®Google Scholar
• Davidson TJ, Harel S, Arboleda VA et al. Highly efficient small interfering RNA delivery to primary mammalian neurons induces microRNA-like effects before mRNA degradation. J. Neurosci. 24(45), 10040–10046 (2004).
   PubMed Web of Science ®Google Scholar
• Soutschek J, Akinc A, Bramlage B et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432(7014), 173–178 (2004).
   PubMed Web of Science ®Google Scholar
• Morrissey DV, Lockridge JA, Shaw L et al. Potent and persistent in vivo antiHBV activity of chemically modified siRNAs. Nature Biotechnol. 23(8), 1002–1007 (2005).
   PubMed Web of Science ®Google Scholar
• Morrissey DV, Blanchard K, Shaw L et al. Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication. Hepatology 41(6), 1349–1356 (2005).
   PubMed Web of Science ®Google Scholar
• Eckstein F. Small non-coding RNAs as magic bullets. Trends Biochem. Sci. 30(8), 445–452 (2005).
   PubMed Web of Science ®Google Scholar
• Manoharan M. RNA interference and chemically modified small interfering RNAs. Curr. Opin. Chem. Biol. 8(6), 570–579 (2004).
   PubMed Web of Science ®Google Scholar
• Check E. A crucial test. Nature Med. 11(3), 243–244 (2005).
   PubMed Web of Science ®Google Scholar
• Bressman SB. Dystonia: phenotypes and genotypes. Rev. Neurol. 159(10 Pt 1), 849–856 (2003).
   PubMedGoogle Scholar
• Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 296(5567) 550–553 (2002).
   PubMed Web of Science ®Google Scholar
• Vermeulen A, Behlen L, Reynolds A et al. The contributions of dsRNA structure to Dicer specificity and efficiency. RNA 11(5), 674–682 (2005).
   PubMed Web of Science ®Google Scholar
• Stegmeier F, Hu G, Rickles RJ, Hannon GJ, Elledge SJ. A lentiviral microRNA-based system for single-copy polymerase II-regulated RNA interference in mammalian cells. Proc. Natl Acad. Sci. USA 102(37), 13212–13217 (2005).
   PubMed Web of Science ®Google Scholar
• Song E, Zhu P, Lee SK et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nature Biotechnol. 23(6), 709–717 (2005).
   PubMed Web of Science ®Google Scholar
• Pardridge WM. Intravenous, non-viral RNAi gene therapy of brain cancer. Expert Opin. Biol. Ther. 4(7), 1103–1113 (2004).
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang YF, Bryant J et al. Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer. Clin. Cancer Res. 10(11), 3667–3677 (2004).
   PubMed Web of Science ®Google Scholar
• Zhang Y, Boado RJ, Pardridge WM. In vivo knockdown of gene expression in brain cancer with intravenous RNAi in adult rats. J. Gene Med. 5(12), 1039–1045 (2003).
   PubMed Web of Science ®Google Scholar
• Li MJ, Rossi JJ. Lentiviral vector delivery of recombinant small interfering RNA expression cassettes. Methods Enzymol. 392, 218–226 (2005).
   PubMed Web of Science ®Google Scholar
• Li M, Rossi JJ. Lentiviral vector delivery of siRNA and shRNA encoding genes into cultured and primary hematopoietic cells. Methods Mol. Biol. 309, 261–272 (2005).
   PubMedGoogle Scholar
• Grimm D, Kleinschmidt JA. Progress in adeno-associated virus Type 2 vector production: promises and prospects for clinical use. Hum. Gene Ther. 10(15), 2445–2450 (1999).
   PubMed Web of Science ®Google Scholar
• Burger C, Gorbatyuk OS, Velardo MJ et al. Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Mol. Ther. 10(2), 302–317 (2004).
   PubMed Web of Science ®Google Scholar
• Peden CS, Burger C, Muzyczka N, Mandel RJ. Circulating antiwild type adeno-associated virus Type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated, but not rAAV5-mediated, gene transfer in the brain. J. Virol. 78(12), 6344–6359 (2004).
   PubMed Web of Science ®Google Scholar
• Mandel RJ, Snyder RO, Leff SE. Recombinant adeno-associated viral vector-mediated glial cell line-derived neurotrophic factor gene transfer protects nigral dopamine neurons after onset of progressive degeneration in a rat model of Parkinson’s disease. Exp. Neurol. 160(1), 205–214 (1999).
   PubMed Web of Science ®Google Scholar
• Mandel RJ, Burger C. Clinical trials in neurological disorders using AAV vectors: promises and challenges. Curr. Opin. Mol. Ther. 6(5), 482–490 (2004).
   PubMed Web of Science ®Google Scholar
• Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 297(5580) 353–356 (2002).
   PubMed Web of Science ®Google Scholar
• Thakker DR, Natt F, Husken D et al. Neurochemical and behavioral consequences of widespread gene knockdown in the adult mouse brain by using nonviral RNA interference. Proc. Natl Acad. Sci. USA 101(49), 17270–17275 (2004).
   PubMed Web of Science ®Google Scholar
• Bruijn LI, Miller TM and Cleveland DW. Unraveling the mechanisms involved in motor neurone degeneration in ALS. Ann. Rev. Neurosci. 27, 723–749 (2004).
   PubMed Web of Science ®Google Scholar
• Gonzalez-Alegre P, Paulson HL. Aberrant cellular behavior of mutant torsinA implicates nuclear envelope dysfunction in DYT1 dystonia. J. Neurosci. 24(11), 2593–2601 (2004).
   PubMed Web of Science ®Google Scholar
• Shashidharan P, Sandu D, Potla U et al. Transgenic mouse model of early-onset DYT1 dystonia. Hum. Mol. Genet. 14(1), 125–133 (2005).
   PubMed Web of Science ®Google Scholar
• Yamamoto A, Lucas JJ, Hen R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington’s disease. Cell 101(1), 57–66 (2000).
   PubMed Web of Science ®Google Scholar
• Hobert O. MicroRNAs: all gone and then what? Curr. Biol. 15(10), R387–R389 (2005).
   PubMed Web of Science ®Google Scholar
• Humbert S, Saudou F. Toward cell specificity in SCA1. Neuron 34(5), 669–670 (2002).
   PubMed Web of Science ®Google Scholar
• Paulson H, Ammache Z. Ataxia and hereditary disorders. Neurol. Clin. 19(3), 759–782 (2001).
   PubMed Web of Science ®Google Scholar
• Matilla A, Roberson ED, Banfi S et al. Mice lacking ataxin-1 display learning deficits and decreased hippocampal paired-pulse facilitation. J. Neurosci. 18(14), 5508–5516 (1998).
   PubMed Web of Science ®Google Scholar
• Zu T, Duvick LA, Kaytor MD et al. Recovery from polyglutamine-induced neurodegeneration in conditional SCA1 transgenic mice. J. Neurosci. 24(40), 8853–8861 (2004).
   PubMed Web of Science ®Google Scholar